Cargando…

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment

Background: Despite the guidelines for Economic and Public Health Assessment Committee (CEESP) submission having been available for nearly six years, the dossiers submitted continue to deviate from them, potentially impacting product prices. Objective: to review the reports published by CEESP, analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toumi, Mondher, Motrunich, Anastasiia, Millier, Aurélie, Rémuzat, Cécile, Chouaid, Christos, Falissard, Bruno, Aballéa, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533125/ https://www.ncbi.nlm.nih.gov/pubmed/28804600 http://dx.doi.org/10.1080/20016689.2017.1344088

Ejemplares similares

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

EU pharmaceutical expenditure forecast
por: Urbinati, Duccio, et al.
Publicado: (2014)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
por: Chouaid, Christos, et al.
Publicado: (2016)

Pharmaceutical expenditure forecast model to support health policy decision making
por: Rémuzat, Cécile, et al.
Publicado: (2014)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data
por: Rahhali, Nora, et al.
Publicado: (2015)

Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
por: Hanna, Eve, et al.
Publicado: (2016)

Gene therapies development: slow progress and promising prospect
por: Hanna, Eve, et al.
Publicado: (2017)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

Cost analysis of adverse events associated with non-small cell lung cancer management in France
por: Chouaid, Christos, et al.
Publicado: (2017)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
por: Thokagevistk, Katia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nd6i1b1f6t9r84k0t5dsc45odf